Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Reyal, Fabien ^a   Hajage, David ^a   Savignoni, Alexia ^a   Feron, Jean Guillaume ^a   Bollet, Marc Andrew ^a   Kirova, Youlia ^a   Fourquet, Alain ^a   Pierga, Jean Yves ^a   Cottu, Paul ^a   Dieras, Veronique ^a   Fourchotte, Virginie ^a   Laki, Fatima ^a   Alran, Severine ^a   Asselain, Bernard ^a   Vincent Salomon, Anne ^a   Sigal Zafrani, Brigitte ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SKIN METASTASIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84875088046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055901     Document Type: Article

References (53)

1. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, et al. (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26: 3324-3330.
2. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, et al. (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23: 5993-6001.
3. Balaton AJ, Baviera EE, Galet B, Vaury P, Vuong PN, (1995) [Immunohistochemical evaluation of estrogen and progesterone receptors on paraffin sections of breast carcinomas. Practical thoughts based on the study of 368 cases]. Arch Anat Cytol Pathol 43: 93-100.
4. Balaton AL, Coindre JM, Collin F, Ettore F, Fiche M, et al. (1996) [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology]. Ann Pathol 16: 144-148.
5. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, et al. (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 43: 1548-1555.
6. Bollet MA, Savignoni A, De Koning L, Tran-Perennou C, Barbaroux C, et al. (2009) Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment. Breast Cancer Res 11: R54.
7. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, et al. (2007) Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 82: 272-280.
8. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, et al. (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97: 545-553.
9. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
10. Chia S, Norris B, Speers C, Cheang M, Gilks B, et al. (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26: 5697-5704.
11. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, et al. (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16: 1723-1739.
12. Colozza M, Sidoni A, Piccart-Gebhart M, (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11: 414-415.
13. de Azambuja E, Cardoso F, de Castro GJ, Colozza M, Mano MS, et al. (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504-1513.
14. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
15. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJJ, et al. (2001) National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93: 979-989.
16. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
17. Elston CW, Ellis IO, (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis Histopathology 19: 403-410 Histopathology 41: 151-2, discussion 152-3.
18. Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, et al. (1989) Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 17: 719-725.
19. Freedman G, Fowble B, Hanlon A, Nicolaou N, Fein D, et al. (1999) Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 44: 1005-1015.
20. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329.
21. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144.
22. Goldstein NS, Kestin L, Vicini F, (2003) Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol 120: 500-527.
23. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, et al. (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776-786.
24. Ikeda T, Akiyama F, Hiraoka M, Inaji H, Ohuchi N, et al. (1999) Surgical Margin Status as a Cause of Local Failure after Breast Conserving Therapy. Breast Cancer 6: 93-97.
25. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH, (2003) The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 57: 724-731.
26. Kini VR, Vicini FA, Frazier R, Victor SJ, Wimbish K, et al. (1999) Mammographic, pathologic, and treatment-related factors associated with local recurrence in patients with early-stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys 43: 341-346.
27. Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, et al. (2006) Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 106: 35-41.
28. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, et al. (2009) Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 15: 4181-4190.
29. Kreike B, Hart AA, van de Velde T, Borger J, Peterse H, et al. (2008) Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. Int J Radiat Oncol Biol Phys 71: 1014-1021.
30. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, et al. (1990) Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 8: 591-598.
31. Livi L, Paiar F, Saieva C, Scoccianti S, Dicosmo D, et al. (2007) Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiother Oncol 82: 287-293.
32. McGrath S, Antonucci J, Goldstein N, Wallace M, Mitchell C, et al. (2010) Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation. Am J Clin Oncol 33: 17-22.
33. Neuschatz AC, DiPetrillo T, Safaii H, Price LL, Schmidt-Ullrich RK, et al. (2003) Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 97: 30-39.
34. Oh JL, Bonnen M, Outlaw ED, Schechter NR, Perkins GH, et al. (2006) The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"? Int J Radiat Oncol Biol Phys 65: 1345-1352.
35. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
36. Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, et al. (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18: 1668-1675.
37. Penault-Llorca F, Andre F, Sagan C, Lacroix-Triki M, Denoux Y, et al. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2809-2815.
38. Penault-Llorca F, Vincent-Salomon A, Bellocq JP, Matthieu MC, Grogan GM, et al. (2010) [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol 30: 357-373.
39. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991.
40. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, et al. (1999) Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 17: 3064-3074.
41. Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, et al. (1999) Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 282: 1335-1343.
42. Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, et al. (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74: 1746-1751.
43. Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, et al. (1995) The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 76: 259-267.
44. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
45. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P, (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17: 323-334.
46. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
47. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
48. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, et al. (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23: 603-607.
49. van Diest PJ, Belien JA, Baak JP, (1992) An expert system for histological typing and grading of invasive breast cancer. First set up. Pathol Res Pract 188: 405-409.
50. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, et al. (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575.
51. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, et al. (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19: 1688-1697.
52. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, Schmid CH, Graham R, et al. (1998) Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys 40: 851-858.
53. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA, (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183.